Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.54 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 4/20 | 0.56 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALPG | P10696 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL554666 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL28531710 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL187218 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL592580 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL554665 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL21494443 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL3954408 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL3954410 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL28531712 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Hydrochloric Acid SCHEMBL4634452 | 0.99 | KDM4A (0.55) | KDM4AKDM2AALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288116-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | Stichting Radboud universitair medisch centrum (NL) | 2023-12-13 | — | — | EP | claimed |
| US-20150301058-A1 | BIOMARKER COMPOSITIONS AND METHODS | CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH) | 2015-10-22 | — | — | US | claimed |
| EP-2922861-A1 | BIOMARKER COMPOSITIONS AND METHODS | Caris Science Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014082083-A1 | BIOMARKER COMPOSITIONS AND METHODS | CARIS SCIENCE, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| US-20100222673-A1 | INTRA-OPERATIVE HEAD AND NECK NERVE MAPPING | NOVADAQ TECHNOLOGIES INC. (CA) | 2010-09-02 | — | — | US | claimed |
| WO-2007016790-A1 | INTRA-OPERATIVE HEAD & NECK NERVE MAPPING | NOVADAQ TECHNOLOGIES, INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| WO-1990002334-A1 | REAGENTS AND METHODS FOR DETERMINATION OF ANALYTES | ZYNAXIS TECHNOLOGIES, INC. (US) | 1990-03-08 | — | — | WO | claimed |
| US-12509512-B2 | Semaphorin 3A antibodies and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-12-30 | — | — | US | disclosed |
| US-20250216397-A1 | METHODS FOR CHARACTERISING EXTRACELLULAR VESICLES BY FLUORESCENCE MICROSCOPY, AND METHODS OF IMMOBILISING EXTRACELLULAR VESICLES | Oxford NanoImaging Limited (GB) | 2025-07-03 | — | — | US | disclosed |
| EP-4305183-B1 | METHODS FOR DELIVERING A CARGO INTO A CELL | Trince bv (BE) | 2025-05-07 | — | — | EP | disclosed |
| EP-4490491-A1 | METHODS FOR CHARACTERISING EXTRACELLULAR VESICLES BY FLUORESCENCE MICROSCOPY, AND METHODS OF IMMOBILISING EXTRACELLULAR VESICLES | Oxford Nanoimaging Limited (GB) | 2025-01-15 | — | — | EP | disclosed |
| EP-4445952-A2 | SUNITINIB FORMULATIONS AND METHODS FOR USE THEREOF IN TREATMENT OF GLAUCOMA | The Johns Hopkins University (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240180485-A1 | METHOD AND DEVICE FOR INDUCING HYPOMETABOLIC STATE IN SUBJECT WITH DISEASE | UNIVERSITY OF TSUKUBA (JP) | 2024-06-06 | — | — | US | disclosed |
| WO-1996006859-A9 | TROPHIC FACTORS FOR CENTRAL NERVOUS SYSTEM REGENERATION | — | 1996-05-09 | — | — | WO | disclosed |
| WO-1996006859-A1 | TROPHIC FACTORS FOR CENTRAL NERVOUS SYSTEM REGENERATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1996-03-07 | — | — | WO | disclosed |
| US-5375606-A | Injecting microspheres coupled to bioaffecting compound having detectable moiety, measuring microspheres in volume of blood withdrawn, recovering tissue, extracting compound, measuring intensity, correlating to microspheres, calculating blood flow | ZYNAXIS, INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5256532-A | Coupling analyte to detectable reporter substance | ZYNAXIS TECHNOLOGIES, INC. (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0471792-A4 | METHODS, REAGENTS AND TEST KITS FOR DETERMINATION OF SUBPOPULATIONS OF BIOLOGICAL ENTITIES | — | 1992-09-16 | — | — | EP | disclosed |
| EP-0471792-A1 | METHODS, REAGENTS AND TEST KITS FOR DETERMINATION OF SUBPOPULATIONS OF BIOLOGICAL ENTITIES | Zynaxis Inc. (US) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990014435-A1 | METHODS, REAGENTS AND TEST KITS FOR DETERMINATION OF SUBPOPULATIONS OF BIOLOGICAL ENTITIES | ZYNAXIS TECHNOLOGIES, INC. (US) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250216397-A1 | METHODS FOR CHARACTERISING EXTRACELLULAR VESICLES BY FLUORESCENCE MICROSCOPY, AND METHODS OF IMMOBILISING EXTRACELLULAR VESICLES | EXOSC10, CD63, EXOSC4 | CHRM1 3919/4885CHRM3 3621/4885ACHE 3268/4885 |
| US-12509512-B2 | Semaphorin 3A antibodies and uses thereof | NOTCH3, IL23R, TNFSF11 | CHRM1 3706/4885CHRM3 1894/4885ACHE 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.